Ga-68 Edotreotide

N/A

Report date: 2026/04/30 20:00:20
NME

Base Information

Drug NameGa-68 Edotreotide
Drug Alias NameGallium-68 edotreotide镓[68Ga]伊索曲肽[68Ga-DOTA0,D-Phe1,Tyr3]-octreotide镓[68Ga]-依度曲肽Edotreotide Ga-68 +[14] 
ClassificationDiagnostic agent (In vivo)Radiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Gallium > 68Ga +[5] 
Mechanisms of ActionSomatostatin receptor 2 bindersIonising radiation emittersPositron-emission tomography enhancers
TargetsSomatostatin receptor 2
Therapy Area/IndicationsPancreatic neuroendocrine tumors (pNET)Diagnostic agentsSolid tumours +[16] 
Global Approved IndicationsPancreatic neuroendocrine tumors (pNET)Diagnostic agentsNeuroendocrine Tumors
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2016/12/08
Country/TerritoryUnited StatesSwedenNetherlands +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAdvanced Accelerator Applications Sa
China Registration ClassN/A

Develop Information

Active CompaniesAdvanced Accelerator Applications SaUniversity Medical Center GroningenNational Institutes Of Health +[7] 
Inactive CompaniesUniversity Of California San FranciscoThe University Of IowaThe University Of Texas MD Anderson Cancer Center +[4] 
Active IndicationsPancreatic neuroendocrine tumors (pNET)Diagnostic agentsSolid tumours +[9] 
Inactive Indicationsvon Hippel-Lindau DiseasePituitary NeoplasmsMultiple Endocrine Neoplasia Type 1 +[7] 

Other Information

ATC CodeV09IX
Related LinksWikipediaKEGG